Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00573495 | Multipeptide Vaccine for Advanced Breast Cancer | completed | Phase 1 | 11 | University of PennsylvaniaOTHER | 1 | Sep 29, 2016 | clinicaltrials |
| NCT01451632 | A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers | completed | Phase 1 | 48 | Merrimack PharmaceuticalsINDUSTRY | 1 | Sep 8, 2016 | clinicaltrials |
| NCT02539017 |
| The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer |
| withdrawn |
| Phase 2 |
| 0 |
| First Affiliated Hospital Xi'an Jiaotong UniversityOTHER |
| 1 |
| Aug 10, 2016 |
| clinicaltrials |
| NCT01320540 | 4R for Guideline Indicated BRCA Testing of Breast Center Patients(4R) | completed | — | 75 | Northwestern UniversityOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02627430 | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 26, 2016 | clinicaltrials |
| NCT00635050 | Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin | completed | Phase 2 | 32 | University of Alabama at BirminghamOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT01293032 | Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer | completed | N/A | 59 | Virginia Commonwealth UniversityOTHER | 2 | Jul 12, 2016 | clinicaltrials |
| NCT01655004 | Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD | unknown | N/A | 110 | National University Hospital, SingaporeOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT00486668 | A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer | unknown | Phase 3 | 529 | NSABP Foundation IncNETWORK | 3 | Jun 6, 2016 | clinicaltrials |
| NCT00742222 | Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer(EXIBT) | completed | Phase 4 | 63 | Xoft, Inc.INDUSTRY | 1 | May 17, 2016 | clinicaltrials |
| NCT01288261 | Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer | completed | Phase 1 | 14 | University of ArizonaOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT02511847 | Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib | unknown | Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT01575522 | Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2016 | clinicaltrials |
| NCT00813956 | A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer | completed | Phase 2 | 80 | SanofiINDUSTRY | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01276496 | Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery | completed | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2016 | clinicaltrials |
| NCT02685657 | Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer | unknown | Phase 2 | 164 | Russian Academy of Medical SciencesOTHER | 0 | Feb 22, 2016 | clinicaltrials |
| NCT01426880 | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer(GeparSixto) | completed | Phase 2 / Phase 3 | 595 | GBG Forschungs GmbHOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT02681562 | Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients | unknown | Phase 2 | 45 | Istituti Ospitalieri di CremonaOTHER | 0 | Feb 15, 2016 | clinicaltrials |
| NCT00998738 | Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer | terminated | Phase 3 | 1 | Mayo ClinicOTHER | 1 | Feb 4, 2016 | clinicaltrials |
| NCT01874184 | Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer(DEEM) | completed | N/A | 17 | University of WashingtonOTHER | 1 | Jan 20, 2016 | clinicaltrials |
| NCT00617370 | Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility | completed | N/A | 38 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 23, 2015 | clinicaltrials |
| NCT00636441 | Trial to Evaluate Genomic Expression Profiles to Direct Preoperative Chemotherapy in Early Stage Breast Cancer | terminated | Phase 2 | 56 | Duke UniversityOTHER | 1 | Dec 11, 2015 | clinicaltrials |
| NCT01400399 | Cosmetic Evaluation of Lumpectomy Versus Oncolytic Mammoplasty With Bilateral Breast Reduction for Early Stage Breast Cancer | unknown | — | 84 | Coastal Carolina Radiation OncologyOTHER | 1 | Dec 9, 2015 | clinicaltrials |
| NCT00244881 | A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Dec 7, 2015 | clinicaltrials |
| NCT01391039 | Diagnostic Study of Early Breast Cancer Using Ultrasound | terminated | N/A | 12 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT02616848 | Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers | unknown | Phase 1 | 1 | Istituti Ospitalieri di CremonaOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT02615457 | Huaier Granule in Treating Women With Triple Negative Breast Cancer | unknown | Phase 4 | 300 | Shandong UniversityOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT00148720 | Capecitabine in Women With Operable Breast Cancer | terminated | Phase 2 | 80 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 11, 2015 | clinicaltrials |
| NCT00368875 | Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Nov 5, 2015 | clinicaltrials |
| NCT01677455 | An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer(Enchant) | completed | Phase 2 | 51 | Synta Pharmaceuticals Corp.INDUSTRY | 8 | Nov 5, 2015 | clinicaltrials |
| NCT02595138 | Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer | unknown | Phase 3 | 430 | Chinese Academy of Medical SciencesOTHER | 0 | Nov 3, 2015 | clinicaltrials |
| NCT02580747 | Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso | unknown | Phase 1 | 20 | Chinese PLA General HospitalOTHER | 1 | Oct 20, 2015 | clinicaltrials |
| NCT01509781 | Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study | unknown | Phase 3 | 400 | National Institute of Oncology, HungaryOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT01238133 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer | terminated | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01281163 | Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer | terminated | Phase 1 | 4 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2015 | clinicaltrials |
| NCT00952731 | 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ | completed | Phase 2 | 27 | Northwestern UniversityOTHER | 1 | Jul 21, 2015 | clinicaltrials |
| NCT00857714 | Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast | terminated | N/A | 1 | Indiana UniversityOTHER | 1 | Jul 8, 2015 | clinicaltrials |
| NCT01043003 | Bilingual Breast Cancer Educational Intervention for Hispanic Women With Stage I, Stage II, or Stage III Breast Cancer and Their Families or Caregivers | completed | N/A | 49 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT01149356 | RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer | terminated | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT01281150 | Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT00070252 | Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | completed | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | May 4, 2015 | clinicaltrials |
| NCT01569321 | Diagosis of Breast Carcinoma: Characterization of Breast Lesions With CLEARPEMSONIC : Feasibility Study | terminated | N/A | 10 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT01071564 | RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery | terminated | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00450879 | Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery | terminated | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2015 | clinicaltrials |
| NCT02393105 | Sense of Hope Alleviates Fatigue in Breast Cancer Survivors | unknown | — | 180 | National Taiwan University HospitalOTHER | 1 | Mar 24, 2015 | clinicaltrials |
| NCT00132002 | Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2015 | clinicaltrials |
| NCT00951054 | A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 61 | Nippon Kayaku Co., Ltd.INDUSTRY | 1 | Feb 16, 2015 | clinicaltrials |
| NCT00909441 | Sentinel Node Biopsy Following NeoAdjuvant Chemotherapy in Biopsy Proven Node Positive Breast Cancer(SN-FNAC) | completed | N/A | 153 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Feb 10, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Sep 29, 2016source: clinicaltrials